Tag: <span>Mesothelioma News</span>

Penn Medicine: Immunotherapy drug pembrolizumab shows promise for mesothelioma patients

The PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, shrank or halted growth of tumors in 76 percent of patients with pleural mesothelioma, a rare and deadly form of cancer that arises in the outer lining of the lungs and internal chest wall,…

Immunotherapy Drug Pembrolizumab Shows Early Promise for Mesothelioma Patients

The PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, shrank or halted growth of tumors in 76 percent of patients with pleural mesothelioma, a rare and deadly form of cancer that arises in the outer lining of the lungs and internal chest wall,…

Immune Cell Cancer Immunotherapy Passes First Safety Test in Solid Tumors

Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.

Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting

Bionomics Limited , a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of cancer and diseases of the central nervous system, today announced the presentation of data from three of its most …

FDA Grants AstraZeneca’s Tremelimumab Orphan Drug Status for Mesothelioma

AstraZeneca’s tremelimumab (anti-CTLA-4 monoclonal antibody) has received Orphan Drug status from the FDA for treating malignant mesothelioma.